INFLUENCE OF DENOSUMABLE ON MINERAL BONE TISSUE DENSITY IN WOMEN WITH POSTMENOPAUSAL OSTEOPOROSIS

Yakovenchuk N. N.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Postmenopausal osteoporosis is one of the most common diseases in women. The peculiarity of this disease is the reduction of bone mass. In the trabecular bone there is a violation of histoarchitecture, which is associated with the rupture of bone trabeculae, their relationship with each other, the presence of cracks and microflakes. Compact bone has resorptive cavities. Mechanisms of violations are associated with negative bone remodeling, incrising osteoclastic activity increases after menopause, resulting in a bone resorption process that exceeds bone formation. The basis of the negative remodeling of the bone is the activation of osteoclasts by RANKL receptors, which express osteoblasts. Denosumab is one of the target drugs, which are human monoclonal antibodies (IgG2) that specifically bind to RANKL and inhibit the differentiation of precursor cells in osteoclasts and their activity. The purpose of the study was to assess the bone mineral density (BMD) with postmenopausal osteoporosis women after treatment with denosumab. Object and methods. It was investigated the effectiveness of targeted therapy with denosumab on the Explorer QDR bone densitometer, Holodgic, 131 women with postmenopausal osteoporosis aged 58 to 66 years who were inpatient treatment or were treated outpatiently were screened. The experimental group of women received treatment with denosumab and calcium with vitamin D. The control group consisted of 30 women with osteoporosis treated with calcium alone with vitamin D. Bone mineral density (BMD) was evaluated of in the lumbar spine and proximal femur. Results. In the case of comparison of BMD before and after treatment with denosumab, a statistically significant increase in BMD in the lumbar spine was observed, which was recorded after 6 months, that is, after the first administration of the drug and for the following observation periods – 1; 1,5; 2 and 3 years. A year later, BMD in the lumbar spine was found to be 6.38 %, and the proximal femur was 2.83%. After 3 years, BMD in the lumbar spine in women was increased in 9.1%, and in the proximal femury in 4.18%, it was considered a positive result. Patients in the control group had a BMD at the level of 0.732 ± 0.03 g/cm2 for the first survey period (T-criterion was -2.8), after 3 years – 0.782 ± 0.04 g/cm2 (T-criterion was -2, 7). That is, the treatment of calcium with vitamin D3 only stabilize the BMD, but no increase in BMD was achieved. During the entire period of observation in patients, there was no deterioration in the clinical status and the occurrence of compression fractures of vertebrate and peripheral fractures. The growth rates in women for all terms of the survey remained stable, the average height was (157.5 ± 1.6) cm when included in the study and (157.4 ± 1.5) cm after 3 years. Conclusion. Thus, the study of the effect of the drug denosumab on BMD in elderly women with postmenopausal osteoporosis was conducted. According to bone densitometry, the efficacy of treatment has been demonstrated for all terms of the study, starting at 6 months.

denosumab, women, mineral density of bone tissue, osteopenia, osteoporosis

1. Mc Clung. Denosumab for the treatment of osteoporosis. Osteoporosis and Sarcopenia. 2017 Mar;3(1);8-17.
2. Demontiero O, Vidal C, Duque G. Aging and bone loss: new insights for the clinician. Therapeutic Advances in Musculoskeletal Disease. 2012;4(2):61-76.
3. Gallagher JC, Tella SH. Prevention and treatment of postmenopausal osteoporosis. The Journal of steroid biochemistry and molecular biology. 2014;142:155-70.
4. Sujatha V, Revathi M, Rajakumari H, Sadana A, Radhika Rani KC. Bone density and biochemical Mmarkers of bone turnover in premenopausal women and postemnopausal women. J. of Dental and Medical Sciences. 2015 Aug;14(8):48-52.
5. Takeuchi Y. Innovation of bisphosphonates for improvement of adherence. Clin Calcium. 2017;27(2):197-202.
6. Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, et al. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (Zоledronate treatment in efficacy to osteoporosis; ZONE study). Osteoporos Int. 2017 Jan;28(1):389-98.
7. Adler RA, El Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner. 2016;31:16-35.
8. Hagino H. Bisphosphonate. Nihon Rinsho. 2015 Oct;73(10):1683-9.
9. Altman AR, Tseng WJ, de Bakker CMJ, Huh BK, Chandra A, Qin L, et al. A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone. 2014;61:149-57.
10. Geusens P. New insights into treatment of osteoporosis in postmenopausal women. RMD Open. 2015;1(1):1-5.
11. Tet A. Mechanisms of osteoclast-dependent bone formation. International Bone & Mineral Society. Bonekey Rep. 2013;2:449.
12. Park JH, Lee NK, Lee SY. Current Understanding of RANK Signaling in Osteoclast differentiation and maturation. Mol. Cells. 2017;40(10):70613.
13. Matsuda Y, Motokawa M, Kaku M, Sumi H, Tanne K, Tanimoto K. RANKL and OPG expression: Jiggling force affects root resorption in rats. The Angle Orthodontist. 2017 Jan;87(1):41-8.
14. Michałowska M, Znorko B, Oksztulska-Kolanek E, Kamiński T, Pawlak D. A view at monoclonal antibodies in therapy of osteoporosis. Polish annals of medicine. 2015;22:149-54.
15. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994 Nov;4(6):368-81.
16. Sánchez A, Brun LR, Salerni H, Costanzo PR, González D, Bagur A, et.al. Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis. J Osteoporosis [Internet]. 2016 Aug [cited 2018 June 16];1(1-6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992763
17. Mc Clung MR, Lewiecki EM, Geller ML, Bolognese MA, Peacock M, Weinstein RL, et al. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial. Osteoporos Int. 2013 Jan;24(1):227-35.
18. Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical trials express: fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis: denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99:2599-607.
19. Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, et al. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos Int. 2015 Feb;26(2):765-74.
20. Zaheer S, LeBoff M, Lewiecki EM. Denosumab for the Treatment of Osteoporosis. Expert opinion on drug metabolism & toxicology. 2015;11(3):461-70. 

«Bulletin of problems biology and medicine» Issue 3 (145), 2018 year, 207-210 pages, index UDK 615.038-616-08-039.73.71-007.234

10.29254/2077-4214-2018-3-1-145-207-210